Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a ...
Southern Methodist University biology researchers are uncovering how brain, heart, and lung connections may hold the key to ...
New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
Hundreds of children in England with a rare and severe form of epilepsy are set to benefit from a new drug being rolled out ...
Hundreds of children with a rare and severe form of epilepsy are hoping a new drug being rolled out on the NHS may provide a ...
A new treatment option has become available for severe epilepsy: fenfluramine, which is now available on the NHS ...
Roanoke and Carilion Clinic combined to remake both the skyline and professional prospects in a city looking for a new ...
Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.
Socioeconomic factors, unpredictability complicate diagnosis of episodic disabilities, like epilepsy
New research focuses on diagnostic delays experienced by people with epilepsy, a neurological disorder characterized by unpredictable seizures that affects over 3 million people in the United States ...
Any patient suffering from new or worsening medical symptoms hopes for a relatively quick and accurate diagnosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback